Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: Back to the bench

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1721-1723

  Hui, Chi Hung ^a   Hughes, Timothy P ^a  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE INHIBITOR; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; BMS 825; CYTARABINE; DASATINIB; ENZYME INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

APHERESIS; AUTOGRAFT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG PREFERENCE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; MEDICAL DECISION MAKING; NOTE; PERIPHERAL BLOOD STEM CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION;

ADJUVANTS, IMMUNOLOGIC; COMBINED MODALITY THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PROTO-ONCOGENE PROTEINS C-ABL; RECOMBINANT PROTEINS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33750461666     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600727871     Document Type: Note

References (14)

1. Guilhot, F. (2004) Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: Update from the IRIS Study Blood, 104, pp. 10A. for the IRIS study group
2. Olsson-Strömberg, U and Höglund, M and Björkholm, M and Braide, I and Carlson, K and Gahrton, G and (2006) Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy+ G-CSF in patients with chronic myelogenous leukemia in first chronic phase Leuk Lymphoma, 47, pp. 1768-1773.
3. Bhatia, R and McGlave, P. (2004) Autologous hematopoietic cell transplantation for chronic myeloid leukemia Hematol Oncol Clin N Am, 18, pp. 715-732.
4. O'Brien, S and Guilhot, F and Larson, R and Gathmann, I and Baccarani, M and Cervantes, F and (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med, 348, pp. 994-1004.
5. Hughes, T and Kaeda, K and Branford, S and Rudzki, Z and Hochhaus, A and Hensley, M and (2003) Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med, 349, pp. 1423-1432.
6. Bhatia, R and Holtz, M and Niu, N and Gray, R and Snyder, D and Sawyers, C and (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood, 101, pp. 4701-4707.
7. Branford, S and Rudzki, Z and Harper, A and Grigg, A and Taylor, K and Durrant, S and (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase Leukemia, 17, pp. 2401-2409.
8. Michor, F and Hughes, T and Iwasa, Y and Branford, S and Shah, N and Sawyers, C and (2005) Dynamics of chronic myeloid leukaemia Nature, 435, pp. 1267-1270.
9. Graham, S and Jorgensen, H and Allan, E and Pearson, C and Alcorn, M and Richmond, L and (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood, 99, pp. 319-325.
10. Drummond, M and Martin, D and Clark, R and Byrne, J and Holyoake, T and Lennard, A. (2003) Mobilization of Ph chromosomal-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission Br J Haematol, 123, pp. 479-483.
11. Hui, C and Goh, K and White, D and Branford, S and Grigg, A and Seymour, J and (2003) Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time-PCR Leukemia, 17, pp. 821-828.
12. Kreuzer, K and Kluhs, C and Baskaynak, G and Movassaghi, K and Dorken, B and le Coutre, P. (2004) Filgrastim-induced stem cell mobilisation in chronic myeloid leukaemia patients during imatinib therapy: Safety, feasibility and evidence for an efficient in vivo purging Br J Haematol, 124, pp. 195-199.
13. Perseghin, P and Gambacorti-Passerini, C and Tornaghi, L and Dassi, M and Pioltelli, P and Parma, M and (2005) Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate Transfusion, 45, pp. 1214-1220.
14. Hughes, T and Branford, S. (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia Blood Rev, 20, pp. 29-41.